Request to Join
has invited you to join this group
Prof. Dr. Charles Majoie, MD (m), Professor of neuroradiology , interventional neuroradiologist and head of the department of neuroradiology in the Amsterdam UMC, location AMC, Amsterdam, The Netherlands. He is as a research leader and co-research leader involved in multiple national and international research collaborations in the field of diagnosis and treatment of acute stroke. He was co-research leader of the ground breaking MRCLEAN trial (www.mrclean-trial.org) , that demonstrated a clear improvement in clinical outcome of patients with acute ischemic stroke after endovascular treatment. This changed the practice how patients with severe strokes are now treated worldwide. He is co research leader of the ongoing MRCLEAN-2 trials within the CONTRAST collaboration (www.contrast-consortium.nl) aiming at treating more patients even more effectively. He was Co-PI of the DIRECT-MT trial, executed in 41 hospitals in China (www.direct-mt.com). He is PI of the H2020 EU funded project INSIST, an international research consortium in the field of computational biomedicine, aiming at performing stroke trials in silico models reducing the number of animal experiments and refining human RCTs (www.insist-h2020.eu) . He is founder of the Neurovascular Intervention Center Amsterdam, a multidisciplinary center of excellence, combining patient care, research and education in the field of neurovascular diseases. He is Principal Investigator of the AMC Research Institute and has supervised 25 PhD students and currently supervises another 19. He was Chairman of the Dutch Society of Neuroradiology from 2012-2018. He has (co)authored more than 400 peer-reviewed manuscripts and has a Hirsch index of 44 (Web of Science).
Yvo Roos is Professor of Acute Neurology and vice-head of department in the Amsterdam UMC, location AMC, Amsterdam, The Netherlands. As a AMC principle investigator (PI) he has been focusing his research on the acute treatment of stroke patients. As such, he has set-up and published over the years several large clinical trials on patients with Aneurysmal Subarachnoid Hemorrhage and Intracerebral hemorrhages. The last decade his main focus, however, was on the acute treatment of patients with an ischemic stroke. He initiated a dedicated Acute Brain Care Unit at the emergency department to improve so called door-to-needle times of patients treated with intravenous thrombolysis (Time is Brain principle). This ultra-early treatment system formed the basis for the endovascular treatment setup in the AmsterdamUMC. This treatment protocol also served as a blueprint for the treatment arm of MRCLEAN trial. This trial, published in the NEJM, showed for the first time that outcome of patients with severe ischemic stroke could be improved significantly when the clot is removed directly form the occluded artery through a catheter.
The trial was awarded with several prizes including the 2017 Science and Innovation Award of the Dutch Federation of Medical Specialists. The MRCLEAN trial results are internationally shared within pooled analyses in two projects – as such Yvo is member of the HERMES and the VISTA projects. He is currently one of the executive members of the MRCLEAN Registry study, a population-level real world experience and exemplary for medical registries globally. All patients with acute ischemic stroke who undergo treatment with the catheter in the Netherlands are registered, currently over 4500 patients. Results of the Registry are published and show that endovascular treatment of acute ischemic stroke is at least as effective as shown in the clinical trial.
After the MRCLEAN trial he was PI of the CLOT-MRCLEAN study, also published in the NEJM. This study showed that the effects of treatment are sustainable over time. The study also shows that this treatment is highly cost-effective (not yet published results), which is very important to facilitate the implementation of this new treatment modality all over the world.
Currently he is co-PI of the new MRCLEAN No-IV trial within the CONTRAST-consortium (www.contrast-consortium.nl) investigating the effect of intravenous treatment with rt-Pa besides mechanical thrombectomy. He is also on the steering committee of the DIRECT-MT trial currently presenting its results in the NEJM.
Yvo has (co)authored more than 200 peer-reviewed manuscript and has a Hirsch index of 42 (Google Scholar).
Professor Liu Jianmin is the director of Department of Neurosurgery, Changhai hospital, Shanghai, China and is endeavored in clinical treatment of cerebrovascular diseases for over 30 years. He was one of the forerunners who introduced and enriched Chinese national neurointerventional therapy. As the founder of OCIN (Oriental Conference of Interventional Neuroradiology) since 2001, he had established an international training and education platform for Chinese neurointerventionalists. He is also the Secretary-general of China Stroke Prevention Project Committee of National Health Commission, which focuses on stroke prevention and treatment, provides population data, develops national clinical guidelines, and initiates large research projects around China.
Professor Liu is skilled and experienced in interventional treatment of cerebrovascular disease. He has majored in cerebrovascular disease for 36 years, completed over 10,000 interventional surgery, developed 11 novel neurointerventional techniques, trained >500 medical students. Recently, he has invented the first flow diverter Tubridge stent in China and confirmed its safety and feasibility with a national RCT study (PARAT). He is the PI of DIRECT-MT trial. He has received 20 grants and published more than 500 papers, with 180 SCI indexed. He has a huge influence on the development and education of Chinese stroke prevention and treatment.
Professor Yang Pengfei is the assistant director of Department of Neurosurgery, Changhai hospital, Shanghai, China and majored in interventional treatment of cerebrovascular disease including acute ischemic stroke, intracranial aneurysms, and cerebral artery stenosis etc. As the vice secretary general of Young and Middle-aged Experts Committee of China Stroke Prevention Project, National Health Commission, he made a great contribution to the treatment of stroke in China. He wrote four Chinese guidelines or expert consensus on treatment of different cerebrovascular diseases.
Professor Yang is skilled and experienced in neuro-interventional therapy for over 10 years, especially in the field of mechanical thrombectomy for acute ischemic stroke. As one of the main developers, he was involved to develop several neurointerventional devices including coils, flow diverter, stent retrievers and aspiration catheters etc. He has received 10 research grants and published more than 150 peer-reviewed papers.
Kilian Treurniet MSc. (m) is a PhD candidate in the research group of Prof. Dr. Charles Majoie at the department of radiology & nuclear medicine of the Amsterdam UMC, location AMC in Amsterdam, the Netherlands. He started his PhD trajectory directly after completion of medical school at Leiden University in 2015. Since then he has co-authored multiple papers on the topic of endovascular management of acute ischemic stroke, including post-hoc analyses of the MR CLEAN trial and MR CLEAN Registry, and presented his work at multiple international conferences such as the International Stroke Conference, the European Stroke Organisation Conference and the annual American Society of Neuroradiology meeting. He is also involved with the MR CLEAN-NO IV trial as one of the coordinating PhD students. MR CLEAN-NO IV (www.mrclean-noiv.nl) is one of the randomized clinical trials within the Collaboration for New Treatments of Stroke consortium (CONTRAST, www.contrast-consortium.nl ), and compares endovascular treatment with and without prior IV thrombolysis in patients with anterior circulation large vessel occlusion. In that capacity he had a supportive role in the DIRECT MT team (www.direct-mt.com). Currently, he is a radiology resident at the department of radiology at the HMC (Haaglanden Medisch Centrum) in The Hague, The Netherlands while also finalizing his PhD thesis.
Dr. Bo Hong is professor of neurosurgery and interventional neuroradiology at Changhai Hospital, the Second Military Medical University, Shanghai, China. His clinical focus is endovascular and surgical treatment of cerebral vascular diseases including intracranial aneurysm, acute ischemic stroke, carotid and intracranial artery stenosis, cerebral and spinal vascular malformations. He also does microvascular decompression of trigeminal neuralgia and hemifacial spasm. Dr Hong has authored or co-authored more than 200 publications mostly concerning endovascular treatment of central nervous system vascular diseases. He has been continuously funded by the National Science Foundation of China and participated in one NIH R01 funded study. Dr. Hong has served as the vice chairman of neurointervention committee of the Chinese Medical Doctor Association.
Dr. Zhang Yongwei is an associate professor of Neurology and Neuroradiology at Navy medical university Changhai Hospital, Shanghai, China. Dr. Zhang's clinical and research focuses on ischemic stroke, especially acute ischemic stroke. He is coordinator of the DIRECT-MT trial.